Media Summary: Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, discusses management options for patients ... Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, comments on updates in the management of ... Jorge Nieva, MD, University of California, San Francisco, CA, talks on the latest developments in the treatment of

Kras Mutant Nsclc - Detailed Analysis & Overview

Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, discusses management options for patients ... Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, comments on updates in the management of ... Jorge Nieva, MD, University of California, San Francisco, CA, talks on the latest developments in the treatment of Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the efficacy of immune ... Jong Woo Lee, MD, PhD, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, talks on his highlights ... Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest developments in ...

An overview of current systemic approaches used to manage patients with

Photo Gallery

Understanding NSCLC Treatment When You Have a KRAS Mutation
Treatment strategies for KRAS-mutant NSCLC with co-mutations
What are the latest developments in KRAS-mutant NSCLC?
Advances in the management of KRAS-mutant NSCLC
KRAS Mutation Subtypes in Advanced NSCLC
What is a KRAS mutation in non-small cell lung cancer (NSCLC)?
Terri - How has your KRAS mutation affected the treatment options available to you?
The role of checkpoint inhibitors in KRAS-mutated NSCLC
KRAS-Mutant NSCLC
Highlights from WCLC 2022: KRAS-mutant lung cancer
Targeting non-G12C KRAS mutations in NSCLC
KRAS-Mutant NSCLC: Current Systemic Treatment Options
View Detailed Profile
Understanding NSCLC Treatment When You Have a KRAS Mutation

Understanding NSCLC Treatment When You Have a KRAS Mutation

Learn more about

Treatment strategies for KRAS-mutant NSCLC with co-mutations

Treatment strategies for KRAS-mutant NSCLC with co-mutations

Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, discusses management options for patients ...

What are the latest developments in KRAS-mutant NSCLC?

What are the latest developments in KRAS-mutant NSCLC?

Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, comments on updates in the management of ...

Advances in the management of KRAS-mutant NSCLC

Advances in the management of KRAS-mutant NSCLC

Jorge Nieva, MD, University of California, San Francisco, CA, talks on the latest developments in the treatment of

KRAS Mutation Subtypes in Advanced NSCLC

KRAS Mutation Subtypes in Advanced NSCLC

Considerations for molecular subtypes of

What is a KRAS mutation in non-small cell lung cancer (NSCLC)?

What is a KRAS mutation in non-small cell lung cancer (NSCLC)?

Learn more about

Terri - How has your KRAS mutation affected the treatment options available to you?

Terri - How has your KRAS mutation affected the treatment options available to you?

Learn more about

The role of checkpoint inhibitors in KRAS-mutated NSCLC

The role of checkpoint inhibitors in KRAS-mutated NSCLC

Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the efficacy of immune ...

KRAS-Mutant NSCLC

KRAS-Mutant NSCLC

Advancements in drugs targeting

Highlights from WCLC 2022: KRAS-mutant lung cancer

Highlights from WCLC 2022: KRAS-mutant lung cancer

Jong Woo Lee, MD, PhD, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, talks on his highlights ...

Targeting non-G12C KRAS mutations in NSCLC

Targeting non-G12C KRAS mutations in NSCLC

Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest developments in ...

KRAS-Mutant NSCLC: Current Systemic Treatment Options

KRAS-Mutant NSCLC: Current Systemic Treatment Options

An overview of current systemic approaches used to manage patients with

Future Directions in Managing KRAS-Mutant Advanced NSCLC

Future Directions in Managing KRAS-Mutant Advanced NSCLC

Concluding their discussion on